Non-Invasive Monitoring Systems Aktsia

Non-Invasive Monitoring Systems EBITDA

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Non-Invasive Monitoring Systems (NIMU) seisuga 10. aug 2026 on −160 000,00 USD. Eelmisel aastal oli EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) −177 000,00 USD — muutus −9,60% (kõrgem).

EBITDA

−160 000,00USD

YoY

−9,60%

Viimati uuendatud:

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Non-Invasive Monitoring Systems on 2026 −160 000,00 USD. EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Non-Invasive Monitoring Systems oli 2025 −177 000,00 USD. See väheneb −9,60% kõrgem võrreldes eelmise aastaga.
Access this data via the Eulerpool API

Non-Invasive Monitoring Systems Aktsiate analüüs

Mida Non-Invasive Monitoring Systems teeb? Non-Invasive Monitoring Systems Inc (NIMS) has become a major player in the field of medical diagnostics and monitoring in recent years. The company was founded in 2002 and is headquartered in Miami, Florida. Its focus is on developing and marketing innovative non-invasive technologies that enable better patient care. NIMS' business model is based on the development and marketing of products that allow for fast and accurate diagnosis of various medical conditions. These technologies can be used in various clinical areas such as intensive care, oncology, cardiology, and neurology. The company's goal is to improve patient care by making diagnostics and monitoring faster, more accurate, and more effective. NIMS has several divisions that focus on different medical applications. One of these is the gastrointestinal division, which specializes in the diagnosis and monitoring of gastrointestinal disorders. NIMS offers innovative technologies such as magnetic resonance elastography (MRE-MRI), which allows for the measurement of tissue hardness without invasive procedures. This technology is particularly used in the early detection of cancer, as it enables the detection of tissue changes at an early stage. Another important division of NIMS is cardiovascular monitoring, which aims at the early detection and monitoring of heart diseases. The company offers various non-invasive technologies for this purpose, such as wearable devices for measuring blood pressure and heart rate, or ultrasound for measuring blood flow and vascular stiffness. These technologies are intended to improve the monitoring of patients with heart diseases and to detect complications at an early stage. NIMS also offers innovative diagnostic tools for the early detection of cancer, such as the Cancer Screening Index (CSI). The CSI is a biomarker-based test that calculates the probability of developing certain types of cancer. Various factors such as family history, smoking, or age are taken into account in the calculation. The CSI aims to contribute to the early detection of cancer and thus enable better prognosis. In addition to these products, NIMS is also involved in clinical research. The company offers specialized services such as conducting clinical trials or providing expert opinions. These services are intended to promote the development of new non-invasive diagnostic and monitoring technologies and thus improve overall patient care. Overall, NIMS has become a leading company in the field of non-invasive medical diagnostics and monitoring. The company is constantly striving to advance the development of new innovative technologies to improve patient care and minimize the use of invasive procedures. With its various divisions and products, NIMS is able to cover various medical applications and thus appeal to a broad customer base. Non-Invasive Monitoring Systems on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused Non-Invasive Monitoring Systems aktsia kohta

Non-Invasive Monitoring Systems EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) on 2026. aastal −160 000,00 USD.

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Non-Invasive Monitoring Systems muutus −177 000,00 USD-st −160 000,00 USD-ks, mis vastab −9,60% muutusele. Väärtus on kõrgem kui eelmisel aastal.

Eulpoolist leiate EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) Non-Invasive Monitoring Systems täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

EBITDA mõõdab operatiivset sooritust enne finantsstruktuuri, maksustamiskeskkonna ja mitterahalist amortisatsioonimaksude mõju.

EBITDA = EBIT + amortisatsioon ja amortisatsioon

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) USD on investorite jaoks määrav tegur. Selle näitaja muutused võivad signaliseerida põhialuste paranemist või halvenemist, mõjutades otseselt aktsia hinda. Eulpoolis saate EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) Non-Invasive Monitoring Systems ajaloolist arengut ja reaalajas andmeid jälgida.

Access this data via the Eulerpool API

Kasumi- ja kahjumiaruanne — Non-Invasive Monitoring Systems

Kõik finantsnäitajad — Non-Invasive Monitoring Systems